## Mony J De Leon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8256172/publications.pdf

Version: 2024-02-01

182 papers 25,595 citations

9756 73 h-index 6979 154 g-index

221 all docs

221 docs citations

times ranked

221

24763 citing authors

#	Article	IF	CITATIONS
1	Mild cognitive impairment. Lancet, The, 2006, 367, 1262-1270.	6.3	2,401
2	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.4	1,863
3	Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nature Neuroscience, 1998, 1, 69-73.	7.1	1,425
4	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
5	Clearance systems in the brain—implications for Alzheimer disease. Nature Reviews Neurology, 2015, 11, 457-470.	4.9	1,127
6	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	3.8	1,009
7	Positron Emission Tomography in Evaluation of Dementia. JAMA - Journal of the American Medical Association, 2001, 286, 2120.	3.8	803
8	Multicenter Standardized <sup>18</sup> F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias. Journal of Nuclear Medicine, 2008, 49, 390-398.	2.8	637
9	Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiology of Aging, 2001, 22, 529-539.	1.5	511
10	The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. Acta Neuropathologica, 2010, 119, 755-770.	3.9	485
11	Brain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer's Disease. Annals of the New York Academy of Sciences, 2008, 1147, 180-195.	1.8	462
12	FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 811-822.	3.3	409
13	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 58-69.	0.4	352
14	Combining Early Markers Strongly Predicts Conversion from Mild Cognitive Impairment to Alzheimer's Disease. Biological Psychiatry, 2008, 64, 871-879.	0.7	329
15	Sleep-disordered breathing advances cognitive decline in the elderly. Neurology, 2015, 84, 1964-1971.	1.5	313
16	Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2019-2022.	3.3	295
17	Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiology of Aging, 2008, 29, 676-692.	1.5	292
18	Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiology of Aging, 2010, 31, 1077-1088.	1.5	261

#	Article	IF	CITATIONS
19	Regional Brain Atrophy Rate Predicts Future Cognitive Decline: 6-year Longitudinal MR Imaging Study of Normal Aging. Radiology, 2003, 229, 691-696.	3.6	253
20	Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link. EBioMedicine, 2018, 28, 21-30.	2.7	250
21	Biological markers for therapeutic trials in Alzheimer's disease. Neurobiology of Aging, 2003, 24, 521-536.	1.5	249
22	The cerebrospinal fluid "Alzheimer profile― Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.4	249
23	Microglial activation and tau propagate jointly across Braak stages. Nature Medicine, 2021, 27, 1592-1599.	15.2	235
24	Pre-Clinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging. Journal of Alzheimer's Disease, 2010, 20, 843-854.	1.2	230
25	TNF- $\hat{l}\pm$ and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal subjects. Journal of Neuroimmunology, 2009, 216, 92-97.	1.1	222
26	Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19067-19072.	3.3	218
27	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
28	Hypometabolism and Altered Cerebrospinal Fluid Markers in Normal Apolipoprotein E E4 Carriers with Subjective Memory Complaints. Biological Psychiatry, 2008, 63, 609-618.	0.7	213
29	Periodontal disease associates with higher brain amyloid load in normal elderly. Neurobiology of Aging, 2015, 36, 627-633.	1.5	198
30	Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. Journal of Nuclear Medicine, 2006, 47, 1778-86.	2.8	195
31	Computed Tomography and Positron Emission Transaxial Tomography Evaluations of Normal Aging and Alzheimer's Disease. Journal of Cerebral Blood Flow and Metabolism, 1983, 3, 391-394.	2.4	188
32	Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults. Neurology, 2018, 90, e1789-e1798.	1.5	186
33	Obstructive sleep apnea, cognition and Alzheimer's disease: A systematic review integrating three decades of multidisciplinary research. Sleep Medicine Reviews, 2020, 50, 101250.	3.8	182
34	Relationships between Regional Neuronal Loss and Neurofibrillary Changes in the Hippocampal Formation and Duration and Severity of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1997, 56, 414-420.	0.9	181
35	Sex differences in Alzheimer risk. Neurology, 2017, 89, 1382-1390.	1.5	177
36	Positron Emission Tomography in the Study of Aging and Senile Dementia. Neurobiology of Aging, 1980, 1, 127-131.	1.5	176

#	Article	IF	CITATIONS
37	Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiology of Aging, 2009, 30, 682-690.	1.5	174
38	Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 933-943.	2.5	174
39	Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET. Journal of Nuclear Medicine, 2017, 58, 1471-1476.	2.8	161
40	Subjective Memory Complaints: Presence, Severity and Future Outcome in Normal Older Subjects. Dementia and Geriatric Cognitive Disorders, 2007, 24, 177-184.	0.7	148
41	Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative. Neurolmage, 2010, 51, 654-664.	2.1	145
42	Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer type. Drug Development Research, 1988, 15, 101-114.	1.4	140
43	Early detection of Alzheimer's disease using neuroimaging. Experimental Gerontology, 2007, 42, 129-138.	1.2	140
44	Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid A $\hat{l}^2$ 42 Levels in Cognitively Normal Elderly. Sleep, 2016, 39, 2041-2048.	0.6	140
45	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet Neurology, The, 2018, 17, 860-869.	4.9	140
46	GREATER RISK OF ALZHEIMER'S DISEASE IN OLDER ADULTS WITH INSOMNIA. Journal of the American Geriatrics Society, 2011, 59, 559-562.	1.3	139
47	Alzheimer's Disease and Peripheral Infections: The Possible Contribution from Periodontal Infections, Model and Hypothesis. Journal of Alzheimer's Disease, 2008, 13, 437-449.	1,2	137
48	Association of Cerebral Amyloid- $\hat{l}^2$ Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
49	Detection of amyloid plaques targeted by USPIO-Aβ1–42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. NeuroImage, 2011, 55, 1600-1609.	2.1	126
50	Increased fibrillar amyloid-β burden in normal individuals with a family history of late-onset Alzheimer's. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5949-5954.	3.3	125
51	Posterior Cingulate Glucose Metabolism, Hippocampal Glucose Metabolism, and Hippocampal Volume in Cognitively Normal, Late-Middle-Aged Persons at 3 Levels of Genetic Risk for Alzheimer Disease. JAMA Neurology, 2013, 70, 320.	<b>4.</b> 5	123
52	Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study. PLoS ONE, 2018, 13, e0207885.	1.1	123
53	Volumetric analysis of the pre-frontal regions: findings in aging and schizophrenia. Psychiatry Research - Neuroimaging, 2001, 107, 61-73.	0.9	119
54	MRI volume of the amygdala: a reliable method allowing separation from the hippocampal formation. Psychiatry Research - Neuroimaging, 1999, 90, 113-123.	0.9	117

#	Article	IF	CITATIONS
55	Cerebellar atrophy in Alzheimer's disease—clinicopathological correlations. Brain Research, 1999, 818, 41-50.	1.1	111
56	The interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals. Neurobiology of Aging, 2014, 35, 1318-1324.	1.5	109
57	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	3.7	109
58	Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease. Brain Research, 1998, 805, 267-269.	1.1	108
59	Cerebrovascular Reactivity to Carbon Dioxide in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 427-440.	1.2	106
60	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
61	Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery. PLoS ONE, 2017, 12, e0185926.	1.1	95
62	Positron Emission Tomography and Computed Tomography Assessments of the Aging Human Brain. Journal of Computer Assisted Tomography, 1984, 8, 88-94.	0.5	93
63	Corticosteroids, the Aging Brain and Cognition. Trends in Endocrinology and Metabolism, 1999, 10, 92-96.	3.1	93
64	Mild cognitive impairment (MCI): a historical perspective. International Psychogeriatrics, 2008, 20, 18-31.	0.6	93
65	<i>APOE</i> -by-sex interactions on brain structure and metabolism in healthy elderly controls. Oncotarget, 2015, 6, 26663-26674.	0.8	92
66	Detection of Amyloid Plaques Targeted by Bifunctional USPIO in Alzheimer's Disease Transgenic Mice Using Magnetic Resonance Microimaging. PLoS ONE, 2013, 8, e57097.	1.1	91
67	Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. Neurobiology of Aging, 2004, 25, 977-989.	1.5	90
68	Absence of hippocampal volume differences in survivors of the Nazi Holocaust with and without posttraumatic stress disorder. Psychiatry Research - Neuroimaging, 2005, 139, 53-64.	0.9	89
69	Sex-driven modifiers of Alzheimer risk. Neurology, 2020, 95, e166-e178.	1.5	87
70	Plasma tau complements CSF tau and Pâ€ŧau in the diagnosis of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 483-492.	1.2	86
71	Reduced Mitochondria Cytochrome Oxidase Activity in Adult Children of Mothers with Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 483-490.	1.2	85
72	Basal Hypothalamo-Pituitary-Adrenal Axis Activity and Corticotropin Feedback in Young and Older Men: Relationships to Magnetic Resonance Imaging-Derived Hippocampus and Cingulate Gyrus Volumes. Neuroendocrinology, 2002, 75, 241-249.	1.2	84

#	Article	IF	Citations
73	Contribution of Structural Neuroimaging to the Early Diagnosis of Alzheimer's Disease. International Psychogeriatrics, 1997, 9, 183-190.	0.6	82
74	Positron emission tomography studies of normal aging: A replication of PET III and 18-FDG using PET VI and 11-CDG. Neurobiology of Aging, 1987, 8, 319-323.	1.5	81
75	The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiology of Aging, 2009, 30, 672-681.	1.5	80
76	Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. Scientific Reports, 2021, 11, 10867.	1.6	79
77	Periodontal disease as a possible cause for Alzheimer's disease. Periodontology 2000, 2020, 83, 242-271.	6.3	76
78	Mortality and Temporal Course of Probable Alzheimer's Disease: A 5-Year Prospective Study. International Psychogeriatrics, 1996, 8, 291-311.	0.6	75
79	Robust and conventional neuropsychological norms: Diagnosis and prediction of age-related cognitive decline Neuropsychology, 2008, 22, 469-484.	1.0	74
80	Age-related changes in brain: II. Positron emission tomography of frontal and temporal lobe glucose metabolism in normal subjects. Psychiatric Quarterly, 1995, 66, 357-370.	1.1	72
81	Does mild cognitive impairment increase the risk of developing postoperative cognitive dysfunction?. American Journal of Surgery, 2010, 199, 782-788.	0.9	70
82	Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 3-Repeat Tau Protein in Down Syndrome. Journal of Neuropathology and Experimental Neurology, 2011, 70, 36-50.	0.9	69
83	18F-FDG PET Database of Longitudinally Confirmed Healthy Elderly Individuals Improves Detection of Mild Cognitive Impairment and Alzheimer's Disease. Journal of Nuclear Medicine, 2007, 48, 1129-1134.	2.8	68
84	Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies.		

#	Article	IF	Citations
91	Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly. Neurobiology of Aging, 2012, 33, 1215-1227.	1.5	61
92	Sleep oscillation-specific associations with Alzheimer's disease CSF biomarkers: novel roles for sleep spindles and tau. Molecular Neurodegeneration, 2019, 14, 10.	4.4	61
93	A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiology of Aging, 2008, 29, 836-847.	1.5	60
94	Magnetic Resonance Imaging Improves Cerebrospinal Fluid Biomarkers in the Early Detection of Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 351-362.	1.2	60
95	Framingham Cardiovascular Risk Profile Correlates with Impaired Hippocampal and Cortical Vasoreactivity to Hypercapnia. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 671-679.	2.4	59
96	Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiology of Aging, 2013, 34, 22-34.	1.5	58
97	Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer's disease: a cross-sectional study of middle-aged adults from the broader New York City area. BMJ Open, 2018, 8, e019362.	0.8	58
98	Prevalence of the apolipoprotein E $\hat{l}\mu4$ allele in amyloid $\hat{l}^2$ positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
99	Subjective memory complaints in aging are associated with elevated cortisol levels. Neurobiology of Aging, 2005, 26, 1357-1363.	1.5	57
100	Physical Activity, Mediterranean Diet and Biomarkers-Assessed Risk of Alzheimer's: A Multi-Modality Brain Imaging Study. Advances in Molecular Imaging, 2014, 04, 43-57.	0.3	56
101	Clearance of interstitial fluid (ISF) and CSF (CLIC) group—part of Vascular Professional Interest Area (PIA). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12053.	1.2	53
102	Transient and chronic seizureâ€induced inflammation in human focal epilepsy. Epilepsia, 2016, 57, e191-4.	2.6	52
103	Abnormal Intracellular Accumulation and Extracellular A $\hat{l}^2$ Deposition in Idiopathic and Dup15q11.2-q13 Autism Spectrum Disorders. PLoS ONE, 2012, 7, e35414.	1.1	48
104	Focal dilation and paradoxical collapse of cortical fissures and sulci in patients with normal-pressure hydrocephalus. Journal of Neurosurgery, 1998, 89, 742-747.	0.9	47
105	Structural brain changes in normal individuals with a maternal history of Alzheimer's. Neurobiology of Aging, 2011, 32, 2325.e17-2325.e26.	1.5	47
106	Oxidative Stress and Amyloid-Beta Pathology in Normal Individuals with A Maternal History of Alzheimer's. Biological Psychiatry, 2010, 68, 913-921.	0.7	44
107	Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects. Sleep, 2016, 39, 1253-1260.	0.6	44
108	Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiology of Aging, 2011, 32, 2131-2141.	1.5	43

#	Article	IF	CITATIONS
109	Changes in brain functional homogeneity in subjects with Alzheimer's disease. Psychiatry Research - Neuroimaging, 2002, 114, 39-50.	0.9	41
110	Magnetic resonance and PET studies in the early diagnosis of Alzheimer's disease. Expert Review of Neurotherapeutics, 2004, 4, 831-849.	1.4	41
111	The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer's disease. PLoS ONE, 2018, 13, e0191240.	1.1	41
112	Decreased CSF clearance and increased brain amyloid in Alzheimer's disease. Fluids and Barriers of the CNS, 2022, 19, 21.	2.4	41
113	Duration of neurofibrillary changes in the hippocampal pyramidal neurons. Brain Research, 1998, 799, 156-158.	1.1	40
114	Different Relationship Between Systolic Blood Pressure and Cerebral Perfusion in Subjects With and Without Hypertension. Hypertension, 2019, 73, 197-205.	1.3	39
115	Age-related changes in brain: I. Magnetic resonance imaging measures of temporal lobe volumes in normal subjects. Psychiatric Quarterly, 1995, 66, 343-355.	1.1	38
116	Challenges associated with biomarkerâ€based classification systems for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 346-357.	1.2	37
117	Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 49, 93-100.	1.2	35
118	Periodontal disease's contribution to Alzheimer's disease progression inÂDown syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 49-57.	1.2	32
119	Periventricular lucencies in the CT scans of aged and demented patients. Biological Psychiatry, 1986, 21, 960-962.	0.7	31
120	FDG and Amyloid PET in Cognitively Normal Individuals at Risk for Late-Onset Alzheimer's Disease. Advances in Molecular Imaging, 2014, 04, 15-26.	0.3	31
121	Associations of lifestyle and vascular risk factors with Alzheimer's brain biomarker changes during middle age: a 3-year longitudinal study in the broader New York City area. BMJ Open, 2018, 8, e023664.	0.8	30
122	Brain Atrophy of Secondary REM-Sleep Behavior Disorder in Neurodegenerative Disease. Journal of Alzheimer's Disease, 2016, 52, 1101-1109.	1.2	29
123	Hippocampal blood flow in normal aging measured with arterial spin labeling at 3T. Magnetic Resonance in Medicine, 2011, 65, 128-137.	1.9	26
124	Memantine decreases hippocampal glutamate levels: A magnetic resonance spectroscopy study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1005-1012.	2.5	25
125	Basal forebrain septal nuclei are enlarged in healthy subjects prior to the development of Alzheimer's disease. Neurobiology of Aging, 2018, 65, 201-205.	1.5	25
126	Biomarkers for the early diagnosis of Alzheimer's disease. Lancet Neurology, The, 2006, 5, 198-199.	4.9	24

#	Article	IF	Citations
127	Effects of vascular risk factors, statins, and antihypertensive drugs on PiB deposition in cognitively normal subjects. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 95-104.	1.2	24
128	Comparison of the Brain Volume in Essential Tremor and Parkinson's Disease Tremor Using an Automated Segmentation Method. European Neurology, 2015, 73, 303-309.	0.6	23
129	Selfâ€reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease timeâ€dependent progression. Alzheimer's and Dementia, 2021, 17, 226-245.	0.4	23
130	Cortical Laminar Binding of PET Amyloid and Tau Tracers in Alzheimer Disease. Journal of Nuclear Medicine, 2015, 56, 270-273.	2.8	22
131	Reduced incidence of left-handedness in clinically diagnosed dementia of the Alzheimer type. Neurobiology of Aging, 1986, 7, 161-164.	1.5	21
132	Midbrain Atrophy in Vascular Parkinsonism. European Neurology, 2011, 65, 296-301.	0.6	21
133	Relationship between Clinical Parameters and Brain Structure in Sporadic Amyotrophic Lateral Sclerosis Patients According to Onset Type: A Voxel-Based Morphometric Study. PLoS ONE, 2017, 12, e0168424.	1.1	21
134	Anteroposterior Hippocampal Metabolic Heterogeneity: Three-dimensional Multivoxel Proton <sup>1</sup> H MR Spectroscopic Imagingâ€"Initial Findings. Radiology, 2008, 249, 242-250.	3.6	20
135	Militaryâ€related risk factors for dementia. Alzheimer's and Dementia, 2018, 14, 1651-1662.	0.4	18
136	Periodontal dysbiosis associates with reduced CSF $\hat{A}^242$ in cognitively normal elderly. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12172.	1.2	18
137	Quantifying cerebrospinal fluid dynamics: A review of human neuroimaging contributions to CSF physiology and neurodegenerative disease. Neurobiology of Disease, 2022, 170, 105776.	2.1	18
138	Quantitative evaluation of tau PET tracers 18F-THK5351 and 18F-AV-1451 in Alzheimer's disease with standardized uptake value peak-alignment (SUVP) normalization. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1596-1604.	3.3	15
139	The Brain-Nose Interface: A Potential Cerebrospinal Fluid Clearance Site in Humans. Frontiers in Physiology, 2021, 12, 769948.	1.3	15
140	An entorhinal cortex sulcal pattern is associated with Alzheimer's disease. Human Brain Mapping, 2009, 30, 874-882.	1.9	14
141	Multiregional Age-Associated Reduction of Brain Neuronal Reserve Without Association With Neurofibrillary Degeneration or $\hat{I}^2$ -Amyloidosis. Journal of Neuropathology and Experimental Neurology, 2017, 76, 439-457.	0.9	14
142	Quantitative Water Permeability Mapping of Blood-Brain-Barrier Dysfunction in Aging. Frontiers in Aging Neuroscience, 2022, 14, 867452.	1.7	14
143	Shift from fibrillar to nonfibrillar AÄŸ deposits in the neocortex of subjects with Alzheimer disease. Journal of Alzheimer's Disease, 2001, 3, 49-57.	1.2	12
144	Maternal age affects brain metabolism in adult children of mothers affected by Alzheimer's disease. Neurobiology of Aging, 2012, 33, 624.e1-624.e9.	1.5	12

#	Article	IF	Citations
145	Developmental deficits and staging of dynamics of age associated Alzheimerâ $\in$ <sup>M</sup> s disease neurodegeneration and neuronal loss in subjects with Down syndrome. Acta Neuropathologica Communications, 2022, 10, 2.	2.4	12
146	Seeing what Alzheimer saw. Nature Medicine, 2007, 13, 129-131.	15.2	11
147	Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons with Global Deterioration Scale Stage 2 (Subjective Cognitive Decline with Impairment). Journal of Alzheimer's Disease, 2019, 67, 685-705.	1.2	9
148	Cognitive dysfunction in young subjects with periodontal disease. Neurological Sciences, 2021, 42, 4511-4519.	0.9	9
149	Letter to the editor regarding: Summary of the evidence on modifiable risk factors for cognitive decline and dementia: AÂpopulationâ€based perspective. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 385-386.	1.2	8
150	Therapeutic potential for peripheral clearance of misfolded brain proteins. Nature Reviews Neurology, 2018, 14, 637-638.	4.9	8
151	Clinicopathological Staging of Dynamics of Neurodegeneration and Neuronal Loss in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2021, 80, 21-44.	0.9	8
152	Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's. Contemporary Clinical Trials, 2021, 107, 106488.	0.8	7
153	Diffusion tensor-based analysis of white matter in the healthy aging canine brain. Neurobiology of Aging, 2021, 105, 129-136.	1.5	7
154	Obstructive Sleep Apnea and Hypertension with Longitudinal Amyloid- $\hat{l}^2$ Burden and Cognitive Changes. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 632-636.	2.5	7
155	Effects of Memantine on Cerebrospinal Fluid Biomarkers of Neurofibrillary Pathology. Journal of Alzheimer's Disease, 2009, 18, 509-513.	1.2	6
156	Obesity and Race May Explain Differential Burden of White Matter Hyperintensity Load. Clinical Interventions in Aging, 2021, Volume 16, 1563-1571.	1.3	6
157	Interactive Associations of Neuropsychiatry Inventory-Questionnaire Assessed Sleep Disturbance and Vascular Risk on Alzheimer's Disease Stage Progression in Clinically Normal Older Adults. Frontiers in Aging Neuroscience, 2021, 13, 763264.	1.7	6
158	Brain oxygen extraction and neural tissue susceptibility are associated with cognitive impairment in older individuals. Journal of Neuroimaging, 2022, 32, 697-709.	1.0	5
159	Fibrillar amyloid- $\hat{l}^2$ affects neurofibrillary changes but only in neurons already involved in neurofibrillary degeneration. Acta Neuropathologica, 2001, 101, 585-590.	3.9	4
160	Evaluation of Early Dementia (Mild Cognitive Impairment). PET Clinics, 2010, 5, 15-31.	1.5	4
161	Precisely-Measured Hydration Status Correlates with Hippocampal Volume in Healthy Older Adults. American Journal of Geriatric Psychiatry, 2019, 27, 653-654.	0.6	4
162	Association Between Systemic Amyloidosis and Intracranial Hemorrhage. Stroke, 2022, 53, STROKEAHA121038451.	1.0	4

#	Article	IF	CITATIONS
163	Statistical Parametric Mapping in Amyloid Positron Emission Tomography. Frontiers in Aging Neuroscience, 2022, 14, 849932.	1.7	4
164	Inge Grundke-Iqbal, Ph.D. (1937–2012): the Discoverer of the Abnormal Hyperphosphorylation of Tau in Alzheimer's Disease. Journal of Molecular Neuroscience, 2013, 49, 430-435.	1.1	3
165	Association between lower body temperature and increased tau pathology in cognitively normal older adults. Neurobiology of Disease, 2022, 171, 105748.	2.1	3
166	Synthesis of $[1\hat{a}\in "11C]$ Butanol via a facile solid phase extraction protocol. Applied Radiation and Isotopes, 2020, 159, 109078.	0.7	2
167	Betahydroxybutyrate Consumption in Autopsy Brain Tissue from Alzheimer's Disease Subjects. Journal of Alzheimer's Disease Reports, 2021, 5, 135-141.	1.2	2
168	Reply: Cerebrospinal Fluid, Hyposmia, and Dementia in Alzheimer Disease: Insights from Dynamic PET and a Hypothesis. Journal of Nuclear Medicine, 2018, 59, 718.2-719.	2.8	1
169	Single Photon Emission Computerized Tomography and Neuropsychological Tests That Predict a Good Response to Donepezil Therapy for Alzheimer's Disease. Dementia and Neurocognitive Disorders, 2015, 14, 106.	0.4	1
170	Heuristic scoring method utilizing FDG-PET statistical parametric mapping in the evaluation of suspected Alzheimer disease and frontotemporal lobar degeneration. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 313-326.	1.0	1
171	Structural and functional neuroimaging in Alzheimer's disease. Neurobiology of Aging, 1986, 7, 396-398.	1.5	O
172	<title>Spatial distribution of residual error in 3D image coregistration: an experimental study. , 1997, , .		0
173	The Alzheimer's Imaging Consortium: Celebrating 20Âyears of creativity and progress. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 3-4.	1.2	O
174	ICâ€Pâ€002: OBSTRUCTIVE SLEEP APNEA, BRAIN BETAâ€AMYLOID MEASURES AND TIMEâ€TOâ€PROGRESSION F COGNITIVE IMPAIRMENT TO ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P15.	ROM MILE	) <sub>0</sub>
175	ICâ€Pâ€154: SLEEP DISORDERED BREATHING AND BRAIN BETAâ€AMYLOID BOTH PREDICT TIMEâ€TOâ€PROGRES FROM NORMAL COGNITION TO MILD COGNITIVE IMPAIRMENT WITH BRAIN BETAâ€AMYLOID MODIFYING THE PROGRESSION RISK. Alzheimer's and Dementia, 2018, 14, P130.	SSION 0.4	O
176	P2â€074: IMPAIRED CSF CLEARANCE AND BRAIN AMYLOID IN ALZHEIMER'S DISEASE: A MULTIâ€TRACER PET STU Alzheimer's and Dementia, 2018, 14, P695.	DY 0.4	0
177	P2â€128: DECREASED TOTAL SLEEP TIME IN AMYLOID NEGATIVE APOE4 CARRIERS: A NEW CLINICAL ENDOPHENOTYPE?. Alzheimer's and Dementia, 2018, 14, P717.	0.4	O
178	P2â€230: CHALLENGES ASSOCIATED WITH BIOMARKERâ€BASED CLASSIFICATIONS SYSTEMS FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P756.	0.4	0
179	ICâ€Pâ€104: LONGITUDINAL CHANGES OF STRUCTURAL AND FUNCTIONAL CONNECTIVITY AND CORRELATIONS WITH GENETICS AND NEUROCOGNITIVE METRICS. Alzheimer's and Dementia, 2019, 15, P90.	0.4	O
180	The LUCINDA trial: Leuprolide + cholinesterase inhibition to reduce neurologic decline in Alzheimer's. Alzheimer's and Dementia, 2020, 16, e038780.	0.4	0

#	Article	IF	CITATIONS
181	Abstract MP13: Evaluation Of The Effect Of Low Grade Inflammation And Hypertension On The Development Of White Matter Lesions. Hypertension, 2021, 78, .	1.3	0
182	Effects of blood pressure on white matter lesions and brain volumes in hypertensive and normotensive subjects Alzheimer's and Dementia, 2021, 17 Suppl 3, e053826.	0.4	0